X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will used in the development of Multikine (leukocyte interleukin), which is designed to help the immune system target the tumor for the treatment of squamous cell carcinoma of the head and neck.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $7.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 13, 2024
Details:
The net proceeds will used in the development of Multikine (leukocyte interleukin), which is designed to help the immune system target the tumor for the treatment of squamous cell carcinoma of the head and neck.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $7.75 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 09, 2024
Details:
The Company intends to use the net proceeds to fund the continued development of Multikine (leukocyte interleukin, injection), an investigational immunotherapeutic agent being developed as a potential treatment for head and neck cancer, and cervical dysplasia.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 20, 2023
Details:
Multikine (Leukocyte Interleukin, Injection) immunotherapy to market for the treatment of newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
Multikine (Leukocyte Interleukin, Injection) immunotherapy to market for the treatment of newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
The Company intends to use the proceeds to fund the continued development of Multikine (leukocyte interleukin, injection), an investigational immunotherapeutic agent being developed as a potential treatment for head and neck cancer, and cervical dysplasia.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 20, 2023
Details:
The Company intends to use the proceeds to fund the continued development of Multikine (leukocyte interleukin, injection), an investigational immunotherapeutic agent being developed as a potential treatment for head and neck cancer, and cervical dysplasia.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 17, 2023
Details:
Multikine (Leukocyte Interleukin, Injection) immunotherapy to market for the treatment of newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2023
Details:
The net proceeds will fund the continued development of Multikine (leukocyte interleukin), an immunotherapeutic agent that is being developed as a potential first-line neoadjuvant therapy in patients with advanced primary squamous cell carcinoma of the head and neck.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Spartan Capital Securities
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 27, 2023
Details:
Multikine (leukocyte interleukin) is designed to help the immune system “see” the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.
Lead Product(s): Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area: Oncology Product Name: Multikine
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
